<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ji S</submitter><funding>Ministry of Science and Technology of China</funding><funding>National Natural Science Foundation of China</funding><pagination>923-934</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9794550</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>45(12)</volume><pubmed_abstract>Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have great potential in applications such as regenerative medicine, cardiac disease modeling, and &lt;i>in vitro&lt;/i> drug evaluation. However, hPSC-CMs are immature, which limits their applications. During development, the maturation of CMs is accompanied by a decline in their proliferative capacity. This phenomenon suggests that regulating the cell cycle may facilitate the maturation of hPSC-CMs. Aurora kinases are essential kinases that regulate the cell cycle, the role of which is not well studied in hPSC-CM maturation. Here, we demonstrate that CYC116, an inhibitor of Aurora kinases, significantly promotes the maturation of CMs derived from both human embryonic stem cells (H1 and H9) and iPSCs (induced PSCs) (UC013), resulting </pubmed_abstract><journal>Molecules and cells</journal><pubmed_title>The Aurora Kinase Inhibitor CYC116 Promotes the Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells.</pubmed_title><pmcid>PMC9794550</pmcid><funding_grant_id>82121005</funding_grant_id><funding_grant_id>81730099</funding_grant_id><funding_grant_id>2017YFA0104002</funding_grant_id><pubmed_authors>Ren X</pubmed_authors><pubmed_authors>Ji S</pubmed_authors><pubmed_authors>Huang C</pubmed_authors><pubmed_authors>Ding X</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Xie X</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>He B</pubmed_authors><pubmed_authors>Tu W</pubmed_authors></additional><is_claimable>false</is_claimable><name>The Aurora Kinase Inhibitor CYC116 Promotes the Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells.</name><description>Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have great potential in applications such as regenerative medicine, cardiac disease modeling, and &lt;i>in vitro&lt;/i> drug evaluation. However, hPSC-CMs are immature, which limits their applications. During development, the maturation of CMs is accompanied by a decline in their proliferative capacity. This phenomenon suggests that regulating the cell cycle may facilitate the maturation of hPSC-CMs. Aurora kinases are essential kinases that regulate the cell cycle, the role of which is not well studied in hPSC-CM maturation. Here, we demonstrate that CYC116, an inhibitor of Aurora kinases, significantly promotes the maturation of CMs derived from both human embryonic stem cells (H1 and H9) and iPSCs (induced PSCs) (UC013), resulting </description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-04-04T19:09:13.001Z</modification><creation>2025-04-04T19:09:13.001Z</creation></dates><accession>S-EPMC9794550</accession><cross_references><pubmed>36572561</pubmed><doi>10.14348/molcells.2022.0077</doi></cross_references></HashMap>